The company is forging ahead with next-generation drug development solutions. Bioengineering specialist Ginkgo Bioworks Holdings (DNA 9.31%) delivered some badly needed good news for investors on Tuesday. Those folks commensurately rewarded the company by trading up its stock during that day's session, and it closed more than 9% higher in price. That was more than enough to crush the broader market that day, at least in respect to the stagnating S&P 500 index. Two new products introduced Ginkgo's news was c ...

Protein large language model (LLM) designed to help enterprises accelerate drug development coming to Google Cloud's Vertex AI Model Garden soon; one of the first-of-its-kind in the industry Model API programmable interface now available for individual scientists and researchers to quickly test and advance work BOSTON, Sept. 17, 2024 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA), which is building the leading platform for cell programming and biosecurity, today announced two new offerings that ...

VANCOUVER, British Columbia, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) a biopharmaceutical company committed to advancing new cancer therapies based on novel DNA-damage response technologies and Variational AI, developer of the Enki™ generative artificial intelligence (AI) platform for drug discovery, announced today a research collaboration aimed at leveraging each company's expertise to identify and develop novel small-molecule therapies against DNA-damage response (DDR) t ...

Could this beaten-down stock turn things around in the near future? If a stock is down more than 90% during the past year, you know there's something seriously wrong with the underlying business. Things have gotten so bad for biotech company Ginkgo Bioworks Holdings (DNA 2.29%) that it recently had to do a 1-for-40 reverse stock split to keep its share price up and stay listed on the New York Stock Exchange. It has been in the midst of a stunning free fall as investors appear to have lost patience with the ...

OAKLAND, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that the United States District Court for the Northern District of California Oakland Division has approved the following announcement of a proposed class action settlement that would benefit purchasers of Ginkgo Bioworks Holdings, Inc. common stock (NYSE: DNA): NOTICE OF PENDENCY AND PROPOSED SETTLEMENT OF CLASS ACTION TO: ALL PERSONS WHO (1) purchased or otherwise acquired shares in Ginkgo Bioworks Holdings, Inc. ("Ginkgo," includ ...

The risks may resolve in a year or so but seizing the opportunities will take longer. When a stock you own is struggling to retain value, it pays to know what new problems might lie awaiting in its future. To have the conviction to retain your shares through a dip, you'll also need to appreciate the upcoming opportunities that might make your patience worth the while. Ginkgo Bioworks (DNA -5.64%) is facing a pair of big risks right now, but it also has a pair of big opportunities that could be enough to tur ...

The company is using artificial intelligence, and planning to help others use AI empowered by its data collection. Ginkgo Bioworks (DNA -5.64%) is a biotech that's going big on artificial intelligence (AI). Between its need to perform core workflows with high efficiency, and its generation of tons of biological and manufacturing data that demand analysis, Ginkgo will likely find AI becoming more important to it over time. That's especially true if it starts selling a key input that other biopharma companies ...

Maravai LifeSciences Holdings, Inc. (MRVI) , through its subsidiaries Cygnus Technologies and TriLink BioTechnologies, has announced the launch of AccuRes Host Cell DNA Quantification Kits. This latest launch blends Cygnus' advanced extraction techniques with TriLink's cutting-edge CleanAmp dNTPs technology. The AccuRes kits offer increased sensitivity and specificity in detecting host cell DNA, ensuring the production of biotherapeutics that meet and exceed the most rigorous regulatory standards. Maravai L ...

In a report released in October 2021, Scorpion Capital alleged Ginkgo Bioworks Holdings Inc of being a "colossal scam", claiming that the company, at a $23 billion valuation, was ridiculously overpriced. Former employees cited in this short report claimed that 9 out of 10 projects launched by the company since its inception have failed. Ginkgo shares crashed 12% on the same day the report was released. Investor sentiment deteriorated further when the Department of Justice launched an investigation into the ...

Its ambitious business model may not be sustainable. Ginkgo Bioworks (DNA -1.81%) stock has had a rough 12 months, falling 88%, and undergoing a reverse stock split on Aug. 20 that left its shares down by around 18% in the aftermath. Depending on which view of the company you subscribe to, things could keep getting worse for shareholders over the next couple of years -- or they could get a lot better. Let's game out a few scenarios so that you can understand whether this stock is worth taking a chance on, o ...